Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267940 · ClinicalTrials.gov registry record · Phase 1
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1 study, sponsored by Halozyme Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT03267940 is a Phase 1 study that was terminated before completion, run by Halozyme Therapeutics. The registered enrollment target is 85 participants.
The verdict
NCT03267940, a Phase 1 study, was terminated before completion, sponsored by Halozyme Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3) cisplatin and gemcitabine (CISGEM).
Interventions
- DRUG Atezolizumab
- DRUG PEGPH20
- DRUG CIS
- DRUG GEM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-10-02 |
| Est. Completion | 2019-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03267940
The ClinicalTrials.gov registry entry for NCT03267940 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Atezolizumab is the first listed.
NCT03267940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03267940 about?
NCT03267940 is a clinical study titled "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma". The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3) cisplatin and gemcitabine (CISGEM).
What is the current status of trial NCT03267940?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2017-10-02. Estimated completion is 2019-11-11.
What interventions are being tested in trial NCT03267940?
The interventions under investigation include: Atezolizumab (DRUG), PEGPH20 (DRUG), CIS (DRUG), GEM (DRUG).
Who is sponsoring clinical trial NCT03267940?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.